COLITIS, ULCERATIVE

This study tests an experimental drug called SAR443122 in 187 adults with moderate to severe ulcerative colitis. Participants receive either one of three doses of the drug or a placebo for up to 52 weeks. The goal is to see if the drug can reduce symptoms and inflammation, and to…

This study looks at the long-term safety of the drug ustekinumab in children aged 2 to 18 with Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a previous ustekinumab study and shown benefit from the drug. The main goal is to m…

This study tests three different doses of an experimental drug called MORF-057 against a placebo in 280 adults with moderate to severe ulcerative colitis. The goal is to see if the drug can safely reduce symptoms and help patients achieve remission. Participants must have had act…

This study tests if dupilumab can help people with moderate to severe ulcerative colitis that has a specific immune feature (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks, and researchers will check if symptoms improve. The goal …

This study tests whether combining two drugs (guselkumab and golimumab) works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 adults who haven't responded well to other advanced treatments will take part. The main goal is to see if t…

This study tests an injected drug called guselkumab to see if it can help people with moderate-to-severe ulcerative colitis achieve remission. About 418 adults who have not responded well to other treatments will receive either the drug or a placebo. The main goal is to check if …

This study tests whether golimumab, a medicine that blocks inflammation, can help children with moderate-to-severe ulcerative colitis achieve remission. About 84 kids will receive the drug by injection. The goal is to reduce symptoms like diarrhea and bleeding, and improve qualit…

This study tests two different maintenance doses of the drug TEV-48574 given as a shot every 4 weeks. It includes 247 adults with moderate to severe ulcerative colitis or Crohn's disease who already completed a previous study. The goal is to see if the drug can keep symptoms unde…

This study tests a drug called guselkumab in children aged 2-17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and sores. The goal is to see if the drug can reduce symptoms and lead to remission. About 112 children will receive the drug, …

This study looks at whether health education from nurses can improve quality of life and reduce anxiety and depression in people who have a stoma after digestive surgery. About 70 adult patients with a permanent or long-term ostomy will take part. They will attend workshops and r…

This study looks at whether acupuncture can reduce disease activity and pain in children with Crohn's disease or ulcerative colitis. About 60 children with mild to moderate symptoms will receive acupuncture alongside their usual medications. Researchers will measure changes in di…

This study is the first time GSK4528287, a drug for inflammatory bowel diseases like ulcerative colitis, is being given to humans. It involves 48 healthy volunteers who receive a single dose to check for side effects, measure drug levels in the blood, and see how the drug works i…

This study looks at 672 adults with moderate to severe ulcerative colitis to find the best treatment target. Participants are split into three groups, each aiming for a different level of improvement: just symptoms, symptoms plus endoscopic healing, or symptoms plus endoscopic an…